Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsFengfeng Bei, E. Antonio Chiocca
Life of this patent
Estimating the term…
Abstract
The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier (BBB), compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM). Further disclosed are a number of potential targeting peptide sequences identified that enhance permeation through the BBB, when inserted into the capsid of an adeno-associated virus (AAV).
Claims15
A method of delivering an immunotherapy agent to a cancer in a subject, the method comprising administering to the subject an adeno-associated virus (AAV) comprising (i) a capsid protein comprising an amino acid sequence that comprises at least four contiguous amino acids from the sequence TVSALFK (SEQ ID NO:8);
- TVSALK (SEQ ID NO:4);
- KLASVT (SEQ ID NO:83);
- or KFLASVT (SEQ ID NO:84), and (ii) a transgene encoding an immunotherapy agent, optionally wherein the cancer cell is in the brain of a human subject.
A method of delivering an immunotherapy agent to a cancer in a subject, the method comprising administering to the subject an adeno-associated virus (AAV) comprising (i) a capsid protein comprising an amino acid sequence that comprises at least four contiguous amino acids from the sequence V[S/p][A/m/t/]L (SEQ ID NO:79), TV[S/p][A/m/t/]L (SEQ ID NO:80), TV[S/p][A/m/t/]LK (SEQ ID NO:81), or TV[S/p][A/m/t/]LFK. (SEQ ID NO:82), and (ii) a transgene encoding an immunotherapy agent, optionally wherein the cancer cell is in the brain of a human subject.
Dependencies are inferred from the claim text.